Home > Psychiatry > ECNP 2020 > Psychosis and Schizophrenia > Prognostic tools in the management of clinical high risk for psychosis

Prognostic tools in the management of clinical high risk for psychosis

Presented By
Prof. Celso Arango & Dr Carrie Bearden
Conference
ECNP 2020
Trial
PSYSCAN, PRONIA, NAPLS
Large consortia such as PSYCAN, PRONIA, and NAPLS have contributed to a fast-growing evidence base and increasing insights into the clinical, cognitive, and biochemical characteristics of patients suffering from psychosis. Prediction tools could considerably contribute to identifying patients at high risk for psychosis, but the development of these instruments has not been straightforward. Although several neuroimaging studies have assessed brain abnormalities associated with the early stages of psychosis, this has not led to any specific tools to aid prediction of psychosis onset nor clinical outcome, according to Prof. Celso Arango (Hospital General Universitario Gregorio Marañón, Spain) [1]. These failures are due to several reasons, including the use of univariate analytical techniques and the lack of statistical power, external validation of potential biomarkers, and integration of non-imaging measures (e.g. genetic, clinical, or cognitive data) [2].


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on